Hepatitis B
Medication adherence and antiviral resistance in patients receiving oral antiviral therapy for chronic hepatitis B
Enrollment status: Actively enrolling
Objective
To study rate of antiviral drug resistance and to characterize patterns of drug resistance mutations in hepatitis B patients receiving nucleos(t)ide analogues in clinical practice.
Inclusion/exclusion criteria
Adults receiving nucleos(t)ide analogues for chronic hepatitis B
Principal investigator: Anna Lok, MD aslok@med.umich.edu
Contact person: Sravanthi Kaza (734) 615-3853 or sravanth@med.umich.edu
Long-term safety and efficacy of tenofovir in patients with chronic hepatitis B
Enrollment status: Study is ongoing but enrollment is closed. Patients will be followed for a total of 8 years.
NIH Hepatitis B Research Network
In September 2008, the NIH launched a Hepatitis B Research Network (http://www.hepbnet.org) comprised of 29 clinical centers (adult and pediatric), a data coordinating center, and an immunology laboratory. The University of Michigan is one of the clinical centers and Dr. Anna Lok chairs the network's steering committee.
This network will conduct observational studies as well as clinical studies of new treatment strategies.
Hepatitis B Research Network – Observational Study
Enrollment status: Actively enrolling
Objective
To study the pattern of hepatitis B in North America and the rates of transition through different phases of chronic HBV infection.
Inclusion/exclusion criteria
Adult patients with hepatitis B who are currently not on any antiviral therapy for hepatitis B (exception: pregnant women).
Principal investigator: Anna Lok, MD aslok@med.umich.edu
Contact person: Sravanthi Kaza: (734) 615-3853 or sravanth@med.umich.edu
Hepatitis B Research Network – Immune-Tolerant Trial
Combination entecavir and peginterferon alfa-2a therapy in hepatitis B e antigen (HBeAg)–positive immune-tolerant adults with chronic hepatitis B
Enrollment status: Actively enrolling
Objective
To determine the efficacy of treatment with 8 weeks of entecavir followed by 40 weeks of both entecavir and peginterferon alfa-2a in HBeAg-positive adults who are in the immune-tolerant phase.
Inclusion/exclusion criteria
Adults with chronic hepatitis B infection, HBeAg-positive, normal to slightly abnormal liver enzyme levels, no previous antiviral treatment.
Study design
Randomized controlled trial comparing treatment (8 weeks entecavir followed by 40 weeks of both entecavir and peginterferon alfa-2a) and no treatment.
Principal investigator: Anna Lok, MD aslok@med.umich.edu
Contact person: Sravanthi Kaza: (734) 615-3853 or sravanth@med.umich.eduHepatitis B Research Network – Immune-Active Trial
Combination therapy of peginterferon alfa-2a and tenofovir versus tenofovir monotherapy in HBeAg-positive and HBeAg-negative chronic hepatitis B
Enrollment status: Actively enrolling
Objective
To compare the long-term efficacy of initial treatment with combination therapy consisting of peginterferon alfa-2a plus tenofovir DF versus tenofovir DF monotherapy.
Inclusion/exclusion criteria
- Adults with chronic hepatitis B infection, slightly abnormal liver enzyme levels (ALT >60 IU/ml for males and >40 IU/ml for females, no or limited previous antiviral treatment.
- Patients with cirrhosis can be included provided no liver failure
- Normal kidney function, no major medical or psychosocial illnesses, can tolerate interferon
Study design
This is a randomized (1:1) trial comparing
- Tenofovir DF 300 mg daily for 192 weeks (4 years) and
- Peginterferon alfa-2a 180 µg weekly for 24 weeks plus tenofovir DF 300 mg daily for 192 weeks (4 years).
Medications, clinical evaluations, and tests associated with the trial will be covered by the study.
Principal investigator: Anna Lok, MD aslok@med.umich.edu
Contact person: Sravanthi Kaza: (734) 615-3853 or sravanth@med.umich.edu
